These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 19417146)

  • 41. Loss of protein kinase Cδ/HuR interaction is necessary to doxorubicin resistance in breast cancer cell lines.
    Latorre E; Castiglioni I; Gatto P; Carelli S; Quattrone A; Provenzani A
    J Pharmacol Exp Ther; 2014 Apr; 349(1):99-106. PubMed ID: 24492650
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Treatment with the PARP-inhibitor PJ34 causes enhanced doxorubicin-mediated cell death in HeLa cells.
    Magan N; Isaacs RJ; Stowell KM
    Anticancer Drugs; 2012 Jul; 23(6):627-37. PubMed ID: 22293659
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Dexrazoxane significantly impairs the induction of doxorubicin resistance in the human leukaemia line, K562.
    Sargent JM; Williamson CJ; Yardley C; Taylor CG; Hellmann K
    Br J Cancer; 2001 Apr; 84(7):959-64. PubMed ID: 11286477
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Topoisomerase 2 alpha: a real predictor of anthracycline efficacy?
    Romero A; Caldés T; Díaz-Rubio E; Martín M
    Clin Transl Oncol; 2012 Mar; 14(3):163-8. PubMed ID: 22374418
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Top2a identifies and provides epigenetic rationale for novel combination therapeutic strategies for aggressive prostate cancer.
    Kirk JS; Schaarschuch K; Dalimov Z; Lasorsa E; Ku S; Ramakrishnan S; Hu Q; Azabdaftari G; Wang J; Pili R; Ellis L
    Oncotarget; 2015 Feb; 6(5):3136-46. PubMed ID: 25605014
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Topoisomerase II-alpha gene deletion is not frequent as its amplification in breast cancer.
    Park K; Han S; Gwak GH; Kim HJ; Kim J; Kim KM
    Breast Cancer Res Treat; 2006 Aug; 98(3):337-42. PubMed ID: 16502015
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Quantum dot-based immunofluorescent imaging and quantitative detection of TOP2A and prognostic value in triple-negative breast cancer.
    Zheng H; Li X; Chen C; Chen J; Sun J; Sun S; Jin L; Li J; Sun S; Wu X
    Int J Nanomedicine; 2016; 11():5519-5529. PubMed ID: 27799773
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Expression and inhibition of BRD4, EZH2 and TOP2A in neurofibromas and malignant peripheral nerve sheath tumors.
    Amirnasr A; Verdijk RM; van Kuijk PF; Taal W; Sleijfer S; Wiemer EAC
    PLoS One; 2017; 12(8):e0183155. PubMed ID: 28813519
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin.
    Hofland KF; Thougaard AV; Sehested M; Jensen PB
    Clin Cancer Res; 2005 May; 11(10):3915-24. PubMed ID: 15897593
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Evaluation of TOP2A as a Predictive Marker for Endometrial Cancer With Taxane-Containing Adjuvant Chemotherapy.
    Ito F; Furukawa N; Nakai T
    Int J Gynecol Cancer; 2016 Feb; 26(2):325-30. PubMed ID: 26588239
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Dexrazoxane abrogates acute doxorubicin toxicity in marmoset ovary.
    Salih SM; Ringelstetter AK; Elsarrag MZ; Abbott DH; Roti EC
    Biol Reprod; 2015 Mar; 92(3):73. PubMed ID: 25609833
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The catalytic DNA topoisomerase II inhibitor dexrazoxane (ICRF-187) induces endopolyploidy in Chinese hamster ovary cells.
    Hasinoff BB; Abram ME; Chee GL; Huebner E; Byard EH; Barnabé N; Ferrans VJ; Yu ZX; Yalowich JC
    J Pharmacol Exp Ther; 2000 Nov; 295(2):474-83. PubMed ID: 11046078
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Chemical, biological and clinical aspects of dexrazoxane and other bisdioxopiperazines.
    Hasinoff BB; Hellmann K; Herman EH; Ferrans VJ
    Curr Med Chem; 1998 Feb; 5(1):1-28. PubMed ID: 9481032
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Sodium salicylate is a novel catalytic inhibitor of human DNA topoisomerase II alpha.
    Bau JT; Kurz EU
    Biochem Pharmacol; 2011 Feb; 81(3):345-54. PubMed ID: 20959117
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Dietary isothiocyanate-induced apoptosis via thiol modification of DNA topoisomerase IIα.
    Lin RK; Zhou N; Lyu YL; Tsai YC; Lu CH; Kerrigan J; Chen YT; Guan Z; Hsieh TS; Liu LF
    J Biol Chem; 2011 Sep; 286(38):33591-600. PubMed ID: 21828038
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Mutual regulation of MDM4 and TOP2A in cancer cell proliferation.
    Liu T; Zhang H; Yi S; Gu L; Zhou M
    Mol Oncol; 2019 May; 13(5):1047-1058. PubMed ID: 30672125
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Selection of human leukemic CEM cells for resistance to the DNA topoisomerase II catalytic inhibitor ICRF-187 results in increased levels of topoisomerase IIalpha and altered G(2)/M checkpoint and apoptotic responses.
    Morgan SE; Cadena RS; Raimondi SC; Beck WT
    Mol Pharmacol; 2000 Feb; 57(2):296-307. PubMed ID: 10648639
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Drug-induced apoptosis is delayed and reduced in XPD lymphoblastoid cell lines: possible role of TFIIH in p53-mediated apoptotic cell death.
    Robles AI; Wang XW; Harris CC
    Oncogene; 1999 Aug; 18(33):4681-8. PubMed ID: 10467415
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical pharmacology of dexrazoxane.
    Hochster HS
    Semin Oncol; 1998 Aug; 25(4 Suppl 10):37-42. PubMed ID: 9768822
    [TBL] [Abstract][Full Text] [Related]  

  • 60. p53 Maintains Genomic Stability by Preventing Interference between Transcription and Replication.
    Yeo CQX; Alexander I; Lin Z; Lim S; Aning OA; Kumar R; Sangthongpitag K; Pendharkar V; Ho VHB; Cheok CF
    Cell Rep; 2016 Apr; 15(1):132-146. PubMed ID: 27052176
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.